Stock Market
Equity markets in India and the US: Sensex, Nifty, Wall Street indices, IPOs and the corporate news that moves stocks.
Latest Stock Market stories
US stocks: US market ends down as oil prices, Treasury yields rise
In a turbulent day for Wall Street, the markets faced declines primarily driven by disappointing performances from Alphabet and Amazon, compounded by increasing...
Bond yields spike and stocks drop — plus, why Boeing is bucking the trend
Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.
Morgan Stanley staffer accidentally emails internal list of over 100 investment-banking deals to clients
A Morgan Stanley staffer accidentally sent clients an internal document detailing more than 100 potential investment-banking deals across Asia, including IPO candidates and transactions involving private equity and pension funds.
Meta is having a ChatGPT moment with Muse. What is it and what makes it so special
The tech world and Wall Street are abuzz with Meta's new AI agent ahead of CEO Mark Zuckerberg's developers conference keynote.
Stocks Drop As Bond Yields Hit 2007 High, Mortgage Rates Break 7%
Spiking interest rates sparked selling on Wall Street on Wednesday, with the 10-year Treasury yield rising to a fresh post-crisis peak.
Ahead of Market: 10 things that will decide stock market action on Thursday
Indian equities closed higher on Wednesday, with Sensex gaining 299 points and Nifty rising 118 points as crude prices eased below $99. Broader markets outperformed, while metals and banking stocks led gains amid stronger domestic growth signals and positive market breadth.
How Meta's Muse AI Agent Is Reshuffling AI Stocks on Wall Street Today
Meta's Muse launch has boosted chipmakers and Shopify while raising fresh questions for brokers and insurers.
10 midcap stocks that soared up to 105% in 6 months; check FII and MF holdings
Over the last six months, the Nifty 50 index has been a flat performer, gaining just under 1%, while the Nifty Midcap 150 index has delivered a 13% gain. But the real story lies beneath the surface. Several midcap stocks significantly outperformed the broader index, posting remarkable gains during the same period. As many as 33 midcap stocks have rallied more than 25% over the past six months. Of these, 10 stocks have soared between 50% and 105%, emerging as the standout performers in the segmen
Vedanta, Welspun, Hindustan Copper, other metal stocks surge up to 4%, Nifty Metal up 1.5%; here’s why
Metal stocks surged during the market hours on Wednesday, September 23, as investors focused on the elevated commodity prices amid a mining policy update from the central government.
Who is Venu Srinivasan? TVS Group veteran headlining the Tata Sons row
Who is Venu Srinivasan? A look at the TVS Motor chairman emeritus and a lifetime vice-chairman of Tata Trusts, now in the news over the Tata Sons IPO vote.
Stock Market Today Live Updates: BSE Sensex jumps over 200 points in opening trade; NSE Nifty50 trades above 23,400
The market outlook remains shaped by a combination of domestic equity weakness, currency movements, global cues and developments in crude oil markets
South Korean solar stocks jump as curbs on Chinese sector expected to remain in place
South Korean solar stocks jumped as U.S. restrictions on Chinese solar products came into focus ahead of the Trump-Xi summit.
September sees biggest IPO rush in nearly 30 years as 30 mainboard issues raise Rs 38,785 crore
This month has also seen a sharp increase in fundraising, with mainboard IPOs raising around ₹38,785 crore, the biggest monthly fundraise since October last y...
Dow Jones Futures: Nasdaq Hits New High; Sandisk, Micron Trigger Buy Signals
Dow Jones futures: The Nasdaq hit a new high with memory giants Sandisk and Micron flashing buy signals. But financials are struggling.
Aurora Cannabis Files Application with Alberta Securities Commission to Protect Company Shareholders Having Identified Several Deficiencies in Curaleaf's Hostile Bid Disclosure
NASDAQ | TSX: ACB Aurora has filed an application with the Alberta Securities Commission for an order requiring Curaleaf to comply with securities laws. Aurora...
ATEC Appoints Tommy Carls Executive Vice President, Data Intelligence and Strategy
CARLSBAD, Calif.--(BUSINESS WIRE)--Alphatec Holdings, Inc. (Nasdaq: ATEC), a spine-focused provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced that Thomas "Tommy" Carls has joined the company as Executive Vice President, Data Intelligence and Strategy. Carls will report directly to Chairman and Chief Executive Officer, Pat Miles, and will serve as a member of ATEC's Senior Leadership Team. In this newly created role, Carls will lead ATEC'
Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval and Commercialization
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced the appointment of Bo Cumbo to its Board of Directors. Concurrent with Mr. Cumbo’s appointment, Edward Kaye, M.D., has retired
Gossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial Hypertension
SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS) (the “Company” or “Gossamer”), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that it submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in September 2026 for seralutinib for the
Arcturus Therapeutics Announces Interim OTC Deficiency Phase 2 Results and Introduces LUNAR 2.0TM Next-Generation mRNA Delivery Platform
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company,” “Arcturus,” Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory therapeutics, today announced encouraging interim Phase 2 results from ARCT-810 in ornithine transcarbamylase (OTC) deficiency and introduced LUNAR 2.0TM, the Company’s next-generation mRNA delivery platform, and additional liver pipeline programs. “The ARCT-810 Phase 2 interim results v
Is Establishment Labs’ (ESTA) Profitability Inflection the Ultimate Buying Opportunity?
For growth investors, Establishment Labs Holdings (NASDAQ:ESTA) presents a compelling equity thesis: a medical aesthetics disruptor transitioning from cash-burning expansion to sustainable, profitable scale. Evaluating the company’s long-term fundamentals, such as its trajectory of multi-year revenue growth, operating cash flow generation, return on invested capital/ROIC, and ultimate free cash flow conversion, reveals a business at [...]
How Info60 covers this topic
Each story below is a short excerpt from reporting by an established publisher, shown in the publisher's own words. We credit the publisher and link to the original article. Stories are matched to this topic by keyword and shown newest first.